Key facts
- It has raised $960K; the latest was Seed Round ($960K) in Dec 2025.
- Notable investors include UntroD, 1stRound, Blockbuster TOKYO, Institute for the Global Entrepreneur, Newsight Tech Angels.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CrestecBio
- ·The full record, as it builds
Funding rounds
No funding rounds for CrestecBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CrestecBio
Developer of polymeric nanomedicines designed to treat oxidative stress-related brain injuries. The company specializes in polymer-based nanotechnologies that target oxidative damage in neurological conditions and utilizes pH-responsive redox nanoparticles with a micelle structure, enabling patients to experience improved recovery outcomes following ischemic stroke by reducing neurological damage and enhancing the effectiveness of thrombectomy procedures.
- Sector
- Healthcare
- HQ
- Tsukuba City, Japan
- Employees
- 3
- Website
- crestecbio.com/
- Ownership
- Privately Held (backing)
CrestecBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CrestecBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CrestecBio in its N-PORT filings yet. We sweep new filings monthly.